Trial Profile
A phase I trial of CC-5013 (lenalidomide) and CCI-779 [temsirolimus] in patients with relapsed or refractory multiple myeloma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Temsirolimus (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.